% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kollr:144788,
      author       = {A. Kollár and C. Rothermundt and F. Klenke and B. Bode and
                      D. Baumhoer and V. Arndt$^*$ and A. Feller},
      collaboration = {N. W. Group},
      title        = {{I}ncidence, mortality, and survival trends of soft tissue
                      and bone sarcoma in {S}witzerland between 1996 and 2015.},
      journal      = {Cancer epidemiology},
      volume       = {63},
      issn         = {1877-7821},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2019-02220},
      pages        = {101596},
      year         = {2019},
      abstract     = {Research on soft-tissue sarcoma (STS) and bone sarcoma (BS)
                      is increasingly in the focus of physicians and
                      pharmaceutical companies. Expanding knowledge has improved
                      the management of sarcoma and possibly survival. Here we
                      provide the first population-based data on time trends of
                      incidence, mortality, and survival of STS and BS diagnosed
                      in Switzerland between 1996 and 2015.We performed a
                      retrospective registry study with data from the National
                      Institute for Cancer Epidemiology and Registration (NICER)
                      database in Switzerland between 1996 and 2015.We identified
                      5384 STS patients and 940 BS patients. The three most common
                      STS subtypes were undifferentiated/unclassified sarcoma
                      $(22.3\%),$ liposarcoma $(20.6\%)$ and leiomyosarcoma
                      $(20.6\%).$ Chondrosarcoma, osteosarcoma and Ewing sarcoma
                      represented $40.4\%,$ $27.0\%$ and $15.2\%$ of the BS group,
                      respectively. The age-standardized incidence and mortality
                      rates in 2011-2015 were 4.43 and 1.42 per 100,000
                      person-years for STS, and 0.91 and 0.42 for BS.
                      Age-standardized incidence of STS in males was significantly
                      higher during 1996-2000 than during 2001-2015; however,
                      mortality rates did not change significantly over time.
                      Five-year relative survival (RS) for STS improved
                      significantly from $56.4\%$ $(95\%CI$ 52.9-59.7 for
                      1996-2001) to $61.6\%$ $(95\%CI$ 58.6-64.4 for 2011-2015)
                      (p = 0.025). No improvement in 5-year RS for BS could be
                      observed (RS 1996-2000: $69.6\%,$ $95\%CI$ 61.2-76.6; RS
                      2011-2015: $73.1\%,$ $95\%CI$ 66.6-78.6;
                      p = 0.479).Incidence rates of STS and BS have been
                      stable since 2001. The longer RS in STS can be attributed to
                      advances in sarcoma patient management.},
      cin          = {C071},
      ddc          = {610},
      cid          = {I:(DE-He78)C071-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31520938},
      doi          = {10.1016/j.canep.2019.101596},
      url          = {https://inrepo02.dkfz.de/record/144788},
}